Comparison of Rigid and Soft-Brace Treatments for Acute Osteoporotic Vertebral Compression Fracture: A Prospective, Randomized, Multicenter Study

Tsuyoshi Kato 1,2,†, Hiroyuki Inose 1,*,†, Shoichi Ichimura 3, Yasuaki Tokuhashi 4, Hiroaki Nakamura 5, Masatoshi Hoshino 5, Daisuke Togawa 6, Toru Hirano 7, Hirotaka Haro 8, Tetsuro Ohba 8, Takashi Tsuji 9, Kимиaki Sato 10, Yutaka Sasao 11, Masahiko Takahata 12, Koji Otani 13, Suketaka Momoshima 14, Ukihide Tateishi 15, Makoto Tomita 16, Ryuichi Takemasa 17, Masato Yuasa 1, Takashi Hirai 1, Toshitaka Yoshii 1 and Atsushi Okawa 1

1 Department of Orthopaedics, Graduate School, Tokyo Medical and Dental University, Tokyo 108-0075, Japan; kato.orth@tmd.ac.jp (T.K.); yuasa.orth@tmd.ac.jp (M.Y.); hirai.orth@tmd.ac.jp (T.H.); yoshii.orth@tmd.ac.jp (T.Y.); okawa.orth@tmd.ac.jp (A.O.)
2 Department of Orthopaedics, Ome Municipal General Hospital, Tokyo 198-0042, Japan
3 Department of Orthopaedics, Kyorin University, Tokyo 181-8611, Japan; ichimura@ks.kyorin-u.ac.jp
4 Department of Orthopaedic Surgery, Nihon University, Tokyo 173-8610, Japan; tokuhashi.yasuaki@nihon-u.ac.jp
5 Department of Orthopedic Surgery, Graduate School of Medicine, Osaka City University, Osaka 545-8585, Japan; hnakamura@med.osaka-cu.ac.jp (H.N.), hoshino717@gmail.com (M.H.)
6 Department of Orthopaedic Surgery, Hamamatsu University of Medicine, Shizuoka 431-3192, Japan; daisuketogawa@wish.ocn.ne.jp
7 Department of Orthopaedic Surgery, Niigata University Medical and Dental General Hospital, Niigata 951-8520, Japan; thirano@med.niigata-u.ac.jp
8 Department of Orthopaedic Surgery, University of Yamanashi, Yamanashi 409-3898, Japan; haro@yamanashi.ac.jp (H.H.); tooba@yamanashi.ac.jp (T.O.)
9 Department of Orthopaedic Surgery, Kitasato University Kitasato Institute Hospital, Tokyo 108-8642, Japan; tsuji9@gmail.com
10 Department of Orthopaedic Surgery, Kurume University School of Medicine, Kurume University, Fukuoka 830-0011, Japan; kimia@med.kurume-u.ac.jp
11 Department of Orthopaedic Surgery, Graduate School, School of Medicine, St. Marianna University, Kanagawa 216-8511, Japan; sasaospine@marianna-u.ac.jp
12 Department of Orthopaedic Surgery, Hokkaido University Graduate School of Medicine, Hokkaido 060-8638, Japan; takahatamasahiko@hotmail.co.jp
13 Department of Orthopaedic Surgery, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan; kojiotani1964@gmail.com
14 Department of Diagnostic Radiology, Center for Preventive Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan; momo@rad.med.keio.ac.jp
15 Department of Diagnostic Radiology, Medical Hospital, Tokyo Medical and Dental University, Tokyo 113-8510, Japan; ttisdrnm@tmd.ac.jp
16 Clinical Research Center, Tokyo Medical and Dental University, Tokyo 113-8510, Japan; tomita.crc@tmd.ac.jp
17 Department of Orthopaedic Surgery, Kochi Medical School, Kochi 783-8505, Japan; takemasa-koc@umin.ac.jp
*
† These authors contributed equally to this manuscript.

Abstract: While bracing is the standard conservative treatment for acute osteoporotic compression fracture, the efficacy of different brace treatments has not been extensively studied. We aimed to clarify and compare the preventive effect of the different brace treatments on the deformity of the vertebral body and other clinical results in this patient cohort. This multicenter nationwide study investigated the preventive effect of the treatment on the deformity of the vertebral body.
prospective randomized study included female patients aged 65–85 years with acute one-level osteoporotic compression fractures. We assigned patients within four weeks of injury to either a rigid-brace treatment or a soft-brace treatment. The main outcome measure was the anterior vertebral body compression percentage at 48 weeks. Secondary outcome measures included scores on the European Quality of Life-5 Dimensions (EQ-5D), visual analog scale (VAS) for lower back pain, and the Japanese Orthopaedic Association Back Pain Evaluation Questionnaire (JOABPEQ). A total of 141 patients were assigned to the rigid-brace group, whereas 143 patients were assigned to the soft-brace group. There were no statistically significant differences in the primary outcome and secondary outcome measures between groups. In conclusion, among patients with fresh vertebral compression fractures, the 12-week rigid-brace treatment did not result in a statistically greater prevention of spinal deformity, better quality of life, or lesser back pain than soft-brace.

**Keywords:** osteoporosis; osteoporotic vertebral compression fracture; brace; quality of life; spinal deformity

1. Introduction

Owing to the aging population, the prevalence of osteoporosis has increased rapidly, and the number of patients with fragile fractures has also increased. Among the fragile fractures, vertebral fractures are the most common [1]. Indeed, the Rotterdam study showed an incidence of 19.6/1000 person-years at ages over 75 years for women [2].

In the acute stage, osteoporotic vertebral fractures cause severe back pain, disability in activities of daily living (ADL), and deterioration of the quality of life (QOL), but their life prognosis has been considered relatively good. However, changes in anterior vertebral height caused by osteoporotic vertebral compression fractures can progress with time and result in spinal deformities, such as degenerative kyphosis [3]. Hyper kyphotic alignment itself imposes stress on the anterior spinal column, increases the risk of new compression fractures, and also disrupts normal body balance, resulting in an increased risk of falls and other fractures [3]. Moreover, other factors that can arise from spinal deformity after osteoporotic vertebral fractures, such as reduced lung function, loss of independence, depression, and chronic pain can negatively impact life [3–5]. Thus, when treating osteoporotic vertebral compression fracture patients, reducing the degree of spinal deformity as much as possible is important for improved QOL after fracture.

The current standard treatment of acute vertebral compression fractures includes continuous bracing for up to 6 to 12 weeks until the acute pain resolves [4,6]. The purposes of braces are controlling back pain by limiting motion, stabilizing injured structures by immobilizing the spine, increasing trunk muscle strength, improving respiratory function, and providing pressure to provide correction or prevent progression of a deformity [7–9]. Rigid braces are commonly custom-made to provide the most support to the spine. Accordingly, the material cost of a rigid brace is more expensive than a soft brace or ready-made brace. However, complications regarding rigid-brace treatments such as pressure injury, discomfort, and emotional distress have been reported [10–12]. The problem is that the current evidence remains insufficient in terms of the efficacy of brace treatment for acute vertebral compression fractures because of the few prospective randomized studies [8–10,13–16]. Besides, even the results of prospective, randomized studies are inconsistent; for example, one study demonstrated that the rigid-brace treatment prevented further vertebral deformity compared to non-brace treatment [13], whereas another study demonstrated that the Oswestry Disability Index scores and progression of spinal deformity were similar among non-brace, soft-brace, and rigid-brace groups [14]. Furthermore, one study demonstrated that patients treated with dynamic orthosis had a greater reduction in pain compared to three point orthosis [9], whereas another study demonstrated that the pain level and functional mobility level were similar between dynamic orthosis and soft lumbar orthosis [15].
As a result, the duration and selection of the type of brace, such as rigid brace, soft brace, or ready-made brace, were at the discretion of each physician [16].

Based on the results of a previous pilot study [13], we hypothesized that a rigid brace is superior to a soft brace in preventing further spinal deformity. This large randomized controlled trial aimed to clarify and to compare the preventive effect of the different brace treatments on the deformity of the vertebral body and other clinical results in patients with vertebral compression fractures.

2. Experimental Section

2.1. Trial Design

We conducted a nationwide, multicenter, open-label, clinical superiority trial in which patients with acute osteoporotic compression fractures were randomly assigned, in a 1:1 ratio, to wear either a rigid brace or soft brace for 12 weeks. This trial was approved by the Tokyo Medical and Dental University ethics review boards (1862), and all participants provided oral and written informed consent. The trial took place in 71 Japanese hospitals. We enrolled patients aged between 65 and 85 years who had received a diagnosis of one fresh osteoporotic compression fracture between T10 and L2 within four weeks of injury. The diagnosis of compression fracture was based on the presence of acute lower back pain and the findings present in their plain lateral radiograph or magnetic resonance imaging (MRI). Exclusion criteria included more than two previous compression fractures from T10 to L2, previous spinal surgery, neurological deficits, inability to complete questionnaires, and serious comorbid conditions such as serious cancer and infection.

Simple randomization was performed with the use of a secure, encrypted, web-based system that enabled computer-generated random treatment assignment. Randomization was stratified according to the age.

2.2. Interventions

Physicians explained the pathological condition to each patient, and upon patient approval, each patient was invited to participate in this study. Patients wore ready-made braces until a custom-made thoracolumbar sacral rigid or soft brace was applied. Patients in the rigid-brace group received a rigid thoracolumbosacral orthosis, which is a single-piece molded plastic brace with an opening on the front (Figure 1). Patients in the soft-brace group received a soft thoracolumbosacral orthosis, which is made from an elastic cotton/nylon material and has steel stays with an opening on the front (Figure 1). In both the rigid-brace and soft-brace groups, braces were to be worn at all times. All participants were instructed to wear the brace for a total of 12 weeks. The brace compliance and use of analgesics were self-reported by the patients during the follow-up assessments. With regard to the use of anti-osteoporosis treatment, patients were only allowed the same medication used before injury or newly prescribed active vitamin D. The participants did not receive financial support for the treatments, including brace application and pain medication.

![Figure 1. Braces. Rigid brace (left) and soft brace (right): anterior view.](image-url)
2.3. **Data Collection and Outcomes**

Outcomes of this trial were evaluated using radiographic findings and patient-reported data obtained from validated questionnaires. The primary outcome was the anterior vertebral body compression percentage (AVBCP) at 48 weeks \([17]\), which was defined as the ratio between the vertical height of the compressed anterior section of the injured vertebral body and the posterior vertebral body height at the same level. AVBCP was measured independently at 0, 12, 24, and 48 weeks after the application of the brace, by two of the co-authors, who were unaware of the treatment method. The mean value of the two evaluators was used. Secondary outcomes were scores on the European Quality of Life-5 Dimensions, 3-Level questionnaire (EQ-5D-3L; which ranges from \(-0.111\) to 1, with higher scores indicating better QOL) \([18]\), visual analog scale (VAS) for lower back pain (which ranges from 0 to 100, with higher scores indicating severe pain) \([19]\), and the Japanese Orthopaedic Association Back Pain Evaluation Questionnaire (JOABPEQ; which scores pain-related disorders, lumbar spine function, walking ability, social life function, and mental health; each score ranging from 0 to 100, with higher scores indicating better function) \([20]\). JOABPEQ is based on the Roland–Morris Disability Questionnaire and Short Form 36. These questionnaires were obtained at a regular hospital visit (0, 12, and 48 weeks after the application of the brace), but completed without the assistance of the surgeon or any other person involved in the trial. In addition, the patients responded to questions related to brace compliance and use of analgesics at 4, 8, and 12 weeks and at 4, 8, 12, 24, and 48 weeks, respectively. Lateral radiography was performed at 0, 12, 24, and 48 weeks after the brace application. All data were collected by a blinded clinical research assistant.

2.4. **Statistical Analysis**

The outcome analysis was performed by comparisons between the rigid-brace and soft-brace groups. On the basis of the results of the previous study of radiological AVBCP \([13]\), we performed a power analysis. A total of 110 patients were needed to detect a significant difference in the radiological AVBCP as a primary outcome, with >80% statistical power. Allowing 20% loss during follow-up, we decided to enroll >140 patients into each arm, yielding a minimum of 280 patients in total.

Differences between the two treatment groups were analyzed using the Mann–Whitney U tests for continuous variables and the Fisher’s exact tests for nominal variables. As an ancillary analysis, we assessed the difference of AVBCP between each follow-up period and the correlation between AVBCP and secondary outcome measures in all patients at 48 weeks. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) \([21,22]\). We imputed the missing data measurements with data obtained by the Multiple Imputation by Chained Equations package in R. We chose 20 iterations for the multiple imputation. All tests were 2-sided, and \(p\)-values < 0.05 were considered significant.

2.5. **Availability of Data and Material**

The datasets generated and/or analyzed during the current study are not publicly available due to conditions of ethical approval but are available from the corresponding author on reasonable request.

2.6. **Trial Registration**

UMIN000014876.

3. **Results**

3.1. **Baseline Characteristics of the Patients**

From August 2014 to September 2016, a total of 382 patients were assessed for eligibility for the study. A total of 284 patients met the inclusion criteria and participated in this study, and were
randomly assigned to a study group. A total of 141 patients were assigned to the rigid-brace group, whereas 143 patients were assigned to the soft-brace group (Figure 2). The baseline characteristics of the patients are shown in Table 1. There are no significant differences between the two treatment groups in any of the pretreatment variables.

![Diagram of participant flow through the study](image)

**Figure 2.** Participant flow through the study. Consolidated Standards of Reporting Trials flow diagram showing patient disposition.

**Table 1.** Baseline characteristics of the patients.

| Characteristic                          | Rigid Brace | Soft Brace |
|----------------------------------------|-------------|------------|
|                                        | $n = 141$   | $n = 143$  |
| Mean age (SD), years                   | 76.0 (5.2)  | 75.5 (5.4) |
| Mean time since fracture, weeks        | 1.5 (1.2)   | 1.5 (1.3)  |
| No previous osteoporosis therapy, n (%)| 21 (15)     | 26 (18)    |
| No prevalent vertebral fracture, n (%) | 107 (76)    | 105 (73)   |
| Any prevalent vertebral fracture, n (%)| 34 (24)     | 38 (27)    |
Table 1. Cont.

| Characteristic               | Rigid Brace | Soft Brace |
|------------------------------|-------------|------------|
|                             | n = 141     | n = 143    |
| Level, n (%)                 |             |            |
| T10                          | 3 (2)       | 3 (2)      |
| T11                          | 13 (9)      | 11 (8)     |
| T12                          | 45 (32)     | 62 (43)    |
| L1                           | 49 (35)     | 46 (32)    |
| L2                           | 31 (22)     | 21 (15)    |
| AVBCP, (%)                   | 72.2 (13.5) | 71.4 (14.3)|
| EQ-5D-3L score               | 0.29 (0.30) | 0.28 (0.28)|
| VAS score for back pain      | 72.1 (28.5) | 77.4 (21.3)|

Table 2. Primary and secondary outcomes.

|                      | Rigid Brace Mean (SD) | Soft Brace Mean (SD) | Difference (95% CI) | p-Value |
|----------------------|-----------------------|----------------------|---------------------|---------|
| **Primary outcome**  |                       |                      |                     |         |
| AVBCP score          |                       |                      |                     |         |
| Week 12              | 58.5 (15.7)           | 54.6 (16.3)          | −3.9 (−7.8 to −0.03) | 0.04002 * |
| Week 24              | 56.6 (16.9)           | 52.7 (16.9)          | −3.9 (−8.1 to 0.4)  | 0.07    |
| Week 48              | 55.5 (16.2)           | 53.0 (17.3)          | −2.5 (−7.0 to 1.8)  | 0.20    |
| **Secondary outcomes** |                      |                      |                     |         |
| VAS for lower back pain |                       |                      |                     |         |
| Week 12              | 28.9 (24.1)           | 29.1 (23.9)          | 0.2 (−5.6 to 6.1)   | 0.95    |
| Week 48              | 28.2 (25.8)           | 26.3 (27.0)          | −1.9 (−8.7 to 5.1)  | 0.43    |

AVBCP, anterior vertebral body compression percentage; EQ-5D-3L, European Quality of Life-5 Dimensions, 3-Level questionnaire; VAS, visual analog scale; JOABPEQ, Japanese Orthopaedic Association Back Pain Evaluation Questionnaire.

The rate of missing data was similar among the groups at all follow-up time points, and there was no crossover among the groups at any follow-up time points.

3.2. Primary Outcome

There was no significant difference in the AVBCP at 48 weeks between the patients with rigid-brace treatment and those with soft-brace treatment (Figure 3). The mean AVBCP in the rigid-brace group was 55.5 vs 53.0 in the soft-brace group, resulting in a difference of −2.5 (95% confidence interval (CI), −7.0 to 1.8) in favor of rigid-brace treatments (p = 0.20). Although there was also no significant difference in AVBCP at 24 weeks (p = 0.07), patients in the rigid-brace group had a significantly higher AVBCP than those in the soft-brace group at 12 weeks (p = 0.04) (Figure 3 and Table 3). There was no significant difference in the rate of aggravation of the AVBCP at 48 weeks (91.2% in the rigid-brace group vs 91.2% in the soft-brace group; p > 0.05).
### Table 3. Primary and secondary outcomes.

|                  | Rigid Brace Mean (SD) | Soft Brace Mean (SD) | Difference (95% CI) | p-Value |
|------------------|-----------------------|----------------------|---------------------|---------|
| EQ-5D-3L score   |                       |                      |                     |         |
| Week 12          | 0.70 (0.20)           | 0.72 (0.18)          | 0.02 (−0.03 to 0.06) | 0.58    |
| Week 48          | 0.73 (0.20)           | 0.74 (0.22)          | 0.01 (−0.04 to 0.07) | 0.67    |
| JOABPEQ          |                       |                      |                     |         |
| Pain-related disorder |                   |                      |                     |         |
| Week 12          | 69.5 (31.7)           | 73.1 (30.0)          | 3.6 (−3.9 to 11.1)  | 0.38    |
| Week 48          | 57.3 (29.8)           | 60.6 (29.4)          | 3.3 (−4.4 to 11.0)  | 0.43    |
| Lumbar function  |                       |                      |                     |         |
| Week 12          | 55.9 (30.0)           | 60.1 (28.8)          | 4.2 (−3.0 to 11.3)  | 0.29    |
| Week 48          | 66.4 (28.4)           | 64.8 (31.1)          | −1.6 (−9.5 to 6.1)  | 0.91    |
| Walking ability  |                       |                      |                     |         |
| Week 12          | 54.7 (33.4)           | 55.0 (32.0)          | 0.3 (−7.6 to 8.3)   | 0.92    |
| Week 48          | 61.9 (33.3)           | 62.3 (34.7)          | 0.4 (−8.5 to 9.3)   | 0.82    |
| Social life function |                 |                      |                     |         |
| Week 12          | 50.9 (27.8)           | 53.6 (26.0)          | 2.7 (−3.8 to 9.3)   | 0.36    |
| Week 48          | 57.7 (28.4)           | 63.4 (24.2)          | 5.7 (−1.2 to 12.6)  | 0.12    |
| Mental health    |                       |                      |                     |         |
| Week 12          | 52.1 (19.2)           | 54.5 (19.7)          | 2.4 (−2.3 to 7.1)   | 0.14    |
| Week 48          | 55.9 (19.2)           | 55.6 (19.4)          | −0.3 (−5.3 to 4.8)  | 0.96    |

* p < 0.05; AVBCP, anterior vertebral body compression percentage; EQ-5D-3L, European Quality of Life-5 Dimensions, 3-Level questionnaire; VAS, visual analog scale; JOABPEQ, Japanese Orthopaedic Association Back Pain Evaluation Questionnaire.

**Figure 3.** Temporal trends in the main study outcomes. Anterior vertebral body compression percentage (0 to 100, with higher scores indicating less deformity), visual analog scale (VAS) for lower back pain (0–100, with higher scores indicating severe pain), and European Quality of Life-5 Dimensions 3-Level questionnaire (EQ-5D-3L, −0.111 to 1, with higher scores indicating better quality of life). Shown are the means with 95% CIs at baseline and each follow-up. * p < 0.05; AVBCP, anterior vertebral body compression percentage; VAS, visual analog scale; EQ-5D-3L, European Quality of Life-5 Dimensions 3-Level questionnaire; CI, confidence interval.
The primary outcome data were complete in 80% of the starting cases (228 of 284 available study participants provided final outcome data).

The difference calculated as the mean of the soft-brace group minus the mean of the rigid-brace group; for AVBCP, a negative value denotes a more favorable outcome with rigid-brace treatment, and a lower score indicates greater spinal kyphosis.

3.3. Secondary Outcomes

All scores (VAS, EQ-5D-3L, and JOABPEQ) significantly improved after the application of either brace (Figure 3 and Table 3). Secondary outcome measures showed no significant differences between groups in the results of the VAS score for lower back pain, EQ-5D-3L, and JOABPEQ. The mean VAS score for lower back pain at 48 weeks in the rigid-brace group was 28.2 vs 26.3 in the soft-brace group, resulting in a difference of −1.9 (95% CI, −8.7 to 5.1) in favor of soft-brace treatments (p = 0.43). The mean EQ-5D-3L score at 48 weeks in the rigid-brace group was 0.73 vs 0.74 in the soft-brace group, resulting in a difference of 0.01 (95% CI, −0.04 to 0.07) in favor of soft-brace treatments (p = 0.67). The mean JOABPEQ pain-related disorder score at 48 weeks in the rigid-brace group was 57.3 vs 60.6 in the soft-brace group, resulting in a difference of 3.3 (95% CI, −4.4 to 11.0) in favor of soft-brace treatments (p = 0.43).

3.4. Ancillary Analysis

A post hoc analysis of the total patients showed a significant difference in AVBCP between 0 week and 12 weeks (p < 2 × 10^{-16}), 0 week and 24 weeks (p < 2 × 10^{-16}), 0 week and 48 weeks (p < 2 × 10^{-16}), 12 weeks and 24 weeks (p = 2.7 × 10^{-5}), and 12 weeks and 48 weeks (p = 0.0001). However, there was no significant difference in AVBCP between 24 and 48 weeks (p = 0.85). Interestingly, a post hoc analysis of the total patients showed that there was a significant inverse correlation between AVBCP and VAS for lower back pain (p = 0.003) and a significant correlation between AVBCP and pain-related disorders of JOABPEQ (p = 0.0002) at 48 weeks (Table 4). However, we did not observe any correlation between AVBCP and other factors (Table 4).

### Table 4. Association of AVBCP and secondary outcome measures at 48 weeks.

| Outcome                     | Spearman’s Rank Correlation Rho | p       |
|-----------------------------|---------------------------------|---------|
| EQ-5D-3L score              | 0.09                            | 0.19    |
| VAS score for back pain     | −0.19                           | 0.003 * |
| JOABPEQ score               |                                  |         |
| Pain-related disorders      | 0.24                            | 0.0002 *|
| Lumbar function             | 0.11                            | 0.37    |
| Walking ability             | 0.06                            | 0.31    |
| Social life function        | 0.06                            | 0.39    |
| Mental health               | 0.01                            | 0.87    |

* p < 0.05; AVBCP, anterior vertebral body compression percentage; EQ-5D-3L, European Quality of Life-5 Dimensions, 3-Level questionnaire; VAS, visual analog scale; JOABPEQ, Japanese Orthopaedic Back Pain Evaluation Questionnaire.

3.5. Brace Compliance and the Use of Analgesics

In terms of brace compliance, there were no significant differences between the rigid-brace and soft-brace groups at 4 (p = 0.30), 8 (p = 0.49), and 12 weeks (p = 0.77) (Table 5). Use of analgesics decreased in both groups at all time points, with no statistically significant differences between the groups (Table 6).
Table 5. Brace compliance of the rigid- and soft-brace groups within a 12-week time course.

| Time            | Group       | 4 Weeks | 8 Weeks | 12 Weeks |
|-----------------|-------------|---------|---------|----------|
| <6 h/day        | Rigid brace | 14      | 18      | 24       |
|                 | Soft brace  | 7       | 12      | 22       |
| 6–12 h/day      | Rigid brace | 18      | 20      | 22       |
|                 | Soft brace  | 19      | 22      | 27       |
| >12 h/day       | Rigid brace | 108     | 97      | 84       |
|                 | Soft brace  | 115     | 104     | 84       |
| Numbers         | Rigid brace | 140     | 135     | 130      |
|                 | Soft brace  | 141     | 138     | 133      |
| p-value         |             | 0.30    | 0.49    | 0.77     |

Table 6. Details of the patients in both the rigid- and soft-brace groups with no medication, with non-opiate medication (aspirin, non-steroidal anti-inflammatory drugs), and with weak opiates within a 48-week time course.

| Medication       | Group       | 4 Weeks | 8 Weeks | 12 Weeks | 24 Weeks | 48 Weeks |
|------------------|-------------|---------|---------|----------|----------|----------|
| No medication    | Rigid brace | 43      | 82      | 98       | 102      | 97       |
|                  | Soft brace  | 34      | 77      | 93       | 94       | 96       |
| Non-opiate       | Rigid brace | 86      | 46      | 29       | 19       | 17       |
| medication       | Soft brace  | 92      | 53      | 34       | 25       | 16       |
| Weak opiates     | Rigid brace | 11      | 7       | 3        | 2        | 0        |
|                  | Soft brace  | 15      | 8       | 6        | 5        | 2        |
| Numbers          | Rigid brace | 140     | 135     | 130      | 123      | 114      |
|                  | Soft brace  | 141     | 138     | 133      | 124      | 114      |
| p-value          |             | 0.38    | 0.74    | 0.50     | 0.30     | 0.63     |

3.6. Complications

Seven and nine patients in the rigid-brace and soft-brace groups, respectively, developed new vertebral fractures, showing no significant difference between groups (odds ratio 0.78 (95% CI 0.23 to 2.42) and a percentage difference in rates of −1.3% (95% CI, −6.7% to 4%) in favor of the rigid brace). During the follow-up period, none of the patients in the rigid-brace group underwent a secondary operation, whereas two patients in the soft-brace group did; however, this was not significantly different between the groups (odds ratio 0 (95% CI 0 to 5.39) and a percentage difference in rates of −1.4% (95% CI, −3.3% to 0.5%) in favor of rigid brace).

4. Discussion

This prospective, randomized controlled trial demonstrates that the radiological outcomes of patients treated with a rigid brace or a soft brace for acute vertebral compression fractures are not significantly different at 48 weeks after the application of the brace, although the rigid-brace treatment resulted in better prevention of spinal deformity than the soft-brace treatment at 12 weeks. No differences in the secondary outcomes, including improvement of back pain, QOL status (EQ-5D-3L), and JOABPEQ, were found between the groups at the 48-week follow-up.

It is generally agreed that lumbar compression fractures without neurological deficits should be treated with braces, although there is no consensus on the brace duration [16]. A multicenter cohort study reported that 19.6% of patients did not achieve fracture union at six months [23]. Another prospective study showed that 13.6% of the fresh compression fractures resulted in a delayed union at six months of follow-up [24]. If the external fixation were to be removed, AVBCP would deteriorate especially in delayed union patients. Indeed, AVBCP significantly decreased from 12 weeks to 24 weeks in this study, suggesting that a uniform brace period of 12 weeks may not be
sufficient. On the basis of our results, to prevent further spinal deformity, we recommend that the brace treatment period should be determined individually until bony union is confirmed, not <12 weeks. However, an adequate brace period to prevent further spinal deformity is still not identified, and future investigations regarding this are warranted.

Regarding clinical outcomes, no differences were found in the improvement of back pain, QOL status (EQ-5D-3L), and JOABPEQ between the groups at all time points. Moreover, regarding pain related to compression fractures, there were no significant differences between groups in the use of analgesics throughout the study. Collectively, both braces were equally effective for managing pain and disability of QOL from compression fractures.

Health-related QOL has been affected by spinopelvic malalignment [25]. However, we did not find an association between QOL (EQ-5D-3L) and AVBCP in this study. These results may indicate that the existence of one vertebral fracture does not always deteriorate a patient’s QOL even if the local spinal deformity is severe. However, given that spinal kyphosis is associated with an increased risk of fall and new fractures, it is likely that a patient’s condition may worsen in the future. Thus, without a longer follow-up duration, it may be difficult to gauge the impact of residual spinal deformity after compression fracture on the QOL in this short-term follow-up study of 48 weeks.

We identified a significant inverse association between AVBCP and VAS for low back pain and a significant association between AVBCP and JOABPEQ category pain-related disorders (Table 4). These findings were consistent with the previous notion that patients with low lumbar lordosis presented with back pain [26]. Thus, to reduce the chronic lower back pain after a compression fracture, doctors should develop the appropriate treatment strategy to prevent further spinal deformity.

No significant differences were observed in brace compliance between groups. Although compliance with rigid-brace treatment has been reported to be poor [27], our results showed that patients are more compliant with wearing a rigid brace if doctors provide proper instructions. Regarding the number of patients requiring secondary surgery, there were no significant differences between groups (none in the rigid-brace group, two in the soft-brace group), and the number is quite small. Considering that the VAS score and QOL were improved with time, we do not recommend that patients with acute vertebral fractures undergo vertebroplasty early. In our opinion, vertebroplasty for acute vertebral fractures should be indicated only in a selected subgroup of patients with insufficient pain relief due to a delayed union after the initial conservative treatment.

This study has several limitations. First, physicians and patients could not be blinded to the treatment after they were assigned to a specific study group, but radiographic evaluators at all outcome points were blinded. Second, there has been no consensus on the minimum clinically significant difference of spinal deformity. Therefore, a further study confirming the effect of spinal deformity on back pain and QOL is needed. Third, we did not assign patients into a non-brace group owing to ethical reasons, because a previous study (in which our department participated) demonstrated significant differences in the changes of AVBCP between the rigid-brace and non-brace group, although this study’s protocol was slightly different than that of this previous study [13]. As our study showed a positive outcome with the rigid brace over the soft brace in the initial 12 weeks of treatment, we can also assume that the rates of vertebral collapse would be higher in patients without bracing—at least in the initial 12 weeks of treatment. However, considering that the difference disappeared after brace removal, a further large prospective study on groups with and without braces might be needed to assess the preventive effects of braces on spinal deformity. Fourth, while the rigid-brace group showed significantly higher AVBCP at 12 weeks, this difference disappeared at 24 weeks onwards. This might arise from a smaller difference in AVBCP and a larger standard deviation than we expected in our power analysis. A post hoc sample size calculation showed that to detect a statistically significant between-group difference in AVBCP of 2.5% at 48 weeks, using the standard deviations from our trial, 720 patients would be required in each treatment group. Moreover, no differences in the secondary outcomes, including improvement of back pain, QOL status (EQ-5D-3L), and JOABPEQ, were found
between the groups at 48 weeks. Collectively, we consider that the between-group difference in AVBCP of 2.5%, even if statistically significant, is unlikely to be of clinical significance.

5. Conclusions

We found that the 12-week rigid-brace treatment for acute vertebral compression fractures did not result in statistically greater prevention of spinal deformity, better QOL, or lesser back pain than soft-brace treatment at 48 weeks. Therefore, the routine use of a custom-made rigid brace for acute vertebral compression fractures is not justified.

Author Contributions: Conceptualization, T.K. H.I., and A.O.; Formal analysis, S.M., U.T., M.T. (Makoto Tomita), and R.T.; Funding acquisition, A.O.; Investigation, T.K., H.I., S.I., Y.N., M.H., D.T., T.H. (Toru Hirano), H.H., T.O., T.S., Y.M., M.T. (Masahiko Takahata), K.O., M.Y., T.H. (Takashi Hirai), T.Y., and A.O.; Project administration, A.O.; Writing—original draft, H.I.; Writing—review and editing, T.K., H.I., and A.O.

Funding: This work was supported by Grants-in-Aid from the Japan Agency for Medical Research and Development Grant Number 16dk0110086h0003 (to AO).

Acknowledgments: We would like to thank all the participants and doctors involved in this study. We are also grateful to Tomoko Nakajima for assistance in data acquisition.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Genant, H.K.; Cooper, C.; Poor, G.; Reid, I.; Ehrlich, G.; Kanis, J.; Nordin, B.E.; Barrett-Connor, E.; Black, D.; Bonjour, J.P.; et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos. Int. 1999, 10, 259–264. [CrossRef] [PubMed]
2. Van Der Klift, M.; De Laet, C.E.; Mcloskey, E.V.; Hofman, A.; Pols, H.A. The incidence of vertebral fractures in men and women: The Rotterdam Study. J. Bone Min. Res. 2002, 17, 1051–1056. [CrossRef] [PubMed]
3. Wong, C.C.; McGirt, M.J. Vertebral compression fractures: A review of current management and multimodal therapy. J. Multidiscip. Healthc. 2013, 6, 205–214. [PubMed]
4. Genev, I.K.; Tobin, M.K.; Zaidi, S.P.; Khan, S.R.; Amirouche, F.M.; Mehta, A.I. Spinal Compression Fracture Management: A Review of Current Treatment Strategies and Possible Future Avenues. Glob. Spine J. 2017, 7, 71–82. [CrossRef] [PubMed]
5. Edidin, A.A.; Ong, K.L.; Lau, E.; Kurtz, S.M. Mortality risk for operated and nonoperated vertebral fracture patients in the medicare population. J. Bone Min. Res. 2011, 26, 1617–1626. [CrossRef] [PubMed]
6. Kim, D.H.; Vaccaro, A.R. Osteoporotic compression fractures of the spine; current options and considerations for treatment. Spine J. 2006, 6, 479–487. [CrossRef]
7. Lantz, S.A.; Schultz, A.B. Lumbar spine orthosis wearing. I. Restriction of gross body motions. Spine 1986, 11, 834–837. [CrossRef]
8. Pfeifer, M.; Kohlwey, L.; Begerow, B.; Minne, H.W. Effects of two newly developed spinal orthoses on trunk muscle strength, posture, and quality-of-life in women with postmenopausal osteoporosis: A randomized trial. Am. J. Phys. Med. Rehabil. 2011, 90, 805–815. [CrossRef]
9. Meccariello, L.; Muzii, V.F.; Falzarano, G.; Medici, A.; Carta, S.; Fortina, M.; Ferrata, P. Dynamic corset versus three-point brace in the treatment of osteoporotic compression fractures of the thoracic and lumbar spine: A prospective, comparative study. Aging Clin. Exp. Res. 2017, 29, 443–449. [CrossRef]
10. Giele, B.M.; Wiertsema, S.H.; Beelen, A.; van der Schaaf, M.; Lucas, C.; Been, H.D.; Bramer, J.A. No evidence for the effectiveness of bracing in patients with thoracolumbar fractures. Acta Orthop. 2009, 80, 226–232. [CrossRef]
11. Matsunaga, S.; Hayashi, K.; Naruo, T.; Nozoe, S.I.; Komiya, S. Psychologic management of brace therapy for patients with idiopathic scoliosis. Spine (Phila Pa 1976) 2005, 30, 547–550. [CrossRef]
12. Newman, M.; Lowe, C.M.; Barker, K. Spinal Orthoses for Vertebral Osteoporosis and Osteoporotic Vertebral Fracture: A Systematic Review. Arch. Phys. Med. Rehabil. 2016, 97, 1013–1025. [CrossRef]
13. Chiba, K.; Yoshida, M.; Shinomiya, K.; Satomi, K.; Nagata, K. Conservative management for osteoporotic vertebral fractures: Results of pilot multicenter prospective randomized controlled trial. J.pn. Orthop. Assoc. 2011, 85, 934–941.
14. Kim, H.J.; Yi, J.M.; Cho, H.G.; Chang, B.S.; Lee, C.K.; Kim, J.H.; Yeom, J.S. Comparative study of the treatment outcomes of osteoporotic compression fractures without neurologic injury using a rigid brace, a soft brace, and no brace: A prospective randomized controlled non-inferiority trial. *J. Bone Joint Surg.* 2014, 96, 1959–1966. [CrossRef] [PubMed]

15. Li, M.; Law, S.W.; Cheng, J.; Kee, H.M.; Wong, M.S. A comparison study on the efficacy of SpinoMed(R) and soft lumbar orthosis for osteoporotic vertebral fracture. *Prosthet. Orthot. Int.* 2015, 39, 270–276. [CrossRef] [PubMed]

16. Longo, U.G.; Loppini, M.; Denaro, L.; Maffulli, N.; Denaro, V. Osteoporotic vertebral fractures: Current concepts of conservative care. *Br. Med. Bull.* 2012, 102, 171–189. [CrossRef]

17. Keynan, O.; Fisher, C.G.; Vaccaro, A.; Fehlings, M.G.; Oner, F.C.; Dietz, J.; Kwon, B.; Rampersaud, R.; Bono, C.; France, J.; et al. Radiographic measurement parameters in thoracolumbar fractures: A systematic review and consensus statement of the spine trauma study group. *Spine* 2006, 31, E156–E165. [CrossRef] [PubMed]

18. EuroQol, G. EuroQol—A new facility for the measurement of health-related quality of life. *Health Policy (Amsterdam, Netherlands)* 1990, 16, 199–208.

19. McCormack, H.M.; David, J.D.L.; Sheather, S. Clinical applications of visual analogue scales: A critical review. *Psychol. Med.* 1988, 18, 1007–1019. [CrossRef]

20. Fukui, M.; Chiba, K.; Kawakami, M.; Kikuchi, S.; Konno, S.; Miyamoto, M.; Seichi, A.; Shimamura, T.; et al. JOA Back Pain Evaluation Questionnaire: initial report. *J. Orthop. Sci.* 2007, 12, 443–450. [CrossRef] [PubMed]

21. Team, R.C. *R: A Language and Environment for Statistical Computing*; R Foundation for Statistical Computing: Vienna, Austria, 2013.

22. Kanda, Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. *Bone Marrow Transpl.* 2013, 48, 452–458. [CrossRef] [PubMed]

23. Takahashi, S.; Hoshino, M.; Takayama, K.; Iseki, K.; Sasaoka, R.; Tsuji, T.; Yasuda, H.; Sasaki, T.; Kanematsu, F.; Kono, H.; et al. Predicting delayed union in osteoporotic vertebral fractures with consecutive magnetic resonance imaging in the acute phase: A multicenter cohort study. *Osteoporos. Int.* 2016, 27, 3567–3575. [CrossRef] [PubMed]

24. Yasuda, H.; Hoshino, M.; Tsuji, T.; Terai, H.; Namikawa, T.; Kato, M.; Matsumura, A.; Suzuki, A.; Takayama, K.; Takahashi, S.; et al. Difference of clinical course between cases with bone union and those with delayed union following osteoporotic vertebral fractures. *Arch. Osteoporos.* 2017, 13, 3. [CrossRef] [PubMed]

25. Hasegawa, K.; Okamoto, M.; Hatsushikano, S.; Shimoda, H.; Ono, M.; Watanabe, K. Normative values of spino-pelvic sagittal alignment, balance, age, and health-related quality of life in a cohort of healthy adult subjects. *Eur. Spine J.* 2016, 25, 3675–3686. [CrossRef] [PubMed]

26. Chaléat-Valayer, E.; Mac-Thiong, J.M.; Paquet, J.; Berthonnaud, E.; Siani, F.; Roussouly, P. Sagittal spino-pelvic alignment in chronic low back pain. *Eur. Spine J.* 2011, 20, 634–640. [CrossRef] [PubMed]

27. Lin, J.T.; Lane, J.M. Nonmedical management of osteoporosis. *Curr. Opin. Rheumatol.* 2002, 14, 441–446. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).